Skip to content

Efficacy of Pretreatment with Remimazolam on Prevention of Propofol-Induced Injection Pain in Patients Undergoing Gastroscopy: A Prospective, Sing-Center, Randomized, Double-Blinded and Placebo-Controlled Clinical Trial

Efficacy of Pretreatment with Remimazolam on Prevention of Propofol-Induced Injection Pain in Patients Undergoing Gastroscopy: A Prospective, Sing-Center, Randomized, Double-Blinded and Placebo-Controlled Clinical Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065866
Enrollment
Unknown
Registered
2022-11-17
Start date
2022-11-18
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

propofol-induced injection pain

Interventions

S:Pretreating normal saline 30 seconds before propofol injection
R:Pretreating remimazolam 30 seconds before propofol injection
L:Pretreating lidocaine 30 seconds before propofol injection
E:Pretreating esketamine 30 seconds before propofol injection

Sponsors

Jinan Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients (ASA I ~II, aged 18-65 years, BMI 18~28 kg/m2) undergone selective gastroscopy.

Exclusion criteria

Exclusion criteria: 1. Patients with upper respiratory tract infection and asthma recently; 2. Those who are allergic to experimental drugs; 3. Those with severe risk of elevated blood pressure or intracranial pressure; 4. Hypertension (blood pressure at rest > 170/100); 5. Hyperthyroidism; 6. Serious insufficiency of important organs; 7. Patients with obvious ischemic heart disease; 8. Sinus tachycardia; 9. Abuse of alcohol or analgesic, sedative, antidepressant drugs.

Design outcomes

Primary

MeasureTime frame
incidence of propofol-induced injection pain;

Secondary

MeasureTime frame
the intensity of propofol-induced injection pain;blood pressure;heart rate;SpO2;satisfaction of people;adverse events;

Countries

China

Contacts

Public ContactYuan Ruimei

Jinan Central Hospital; Central Hospital Affiliated to Shandong First Medical University

subave@sina.cn+86 15554127179

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026